- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | TRANSCENTA-B (06628): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, JUNE 30, 2026 | 2 | HKEx | ||
| Fr | TRANSCENTA-B (06628): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| TRANSCENTA Aktie jetzt für 0€ handeln | |||||
| Fr | TRANSCENTA-B (06628): PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND PROPOSED APPOINTMENT OF INDEPENDENT ... | 1 | HKEx | ||
| Do | TRANSCENTA-B (06628): CHANGE OF DIRECTORS AND CHANGE IN THE COMPOSITION OF BOARD COMMITTEES | 1 | HKEx | ||
| 26.05. | TRANSCENTA-B Receives RMB7M Milestone Payment from HiCB Out-Licensing | 4 | AASTOCKS | ||
| 26.05. | TRANSCENTA-B (06628): VOLUNTARY ANNOUNCEMENT-TRANSCENTA REPORTS RECEIPT OF HICB OUT-LICENSING MILESTONE PAYMENT AND STEADY CDMO BUSINESS GROWTH | 1 | HKEx | ||
| 21.05. | TRANSCENTA-B: Positive Interim Data from ozekibart Mid-stage Study; Evaluating Greater China Plan | 1 | AASTOCKS | ||
| 21.05. | TRANSCENTA-B (06628): VOLUNTARY ANNOUNCEMENT-TRANSCENTA'S PARTNER INHIBRX REPORTS POSITIVE UPDATED CRC DATA FOR OZEKIBART AND ANNOUNCES U.S. BLA SUBMISSION ... | 1 | HKEx | ||
| 14.05. | TRANSCENTA-B (06628): POSTPONEMENT OF ANNUAL GENERAL MEETING AND CHANGE OF PERIODS OF CLOSURE OF REGISTER OF MEMBERS | - | HKEx | ||
| 28.04. | TRANSCENTA-B (06628): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED HOLDERS | - | HKEx | ||
| 28.04. | TRANSCENTA-B (06628): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDERS | - | HKEx | ||
| 28.04. | TRANSCENTA-B (06628): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 28.04. | TRANSCENTA-B (06628): 2025 ANNUAL REPORT | - | HKEx | ||
| 23.04. | Transcenta Therapeutics Presents New Data for its Novel LIV1-Targeting ADC TST013 Demonstrating Potent Anti-Tumor Activity in PDX Models of Prostate Cancer and ER Positive /HER2 Negative Breast Cancer | 2 | GlobeNewswire (USA) | ||
| 23.04. | TRANSCENTA-B (06628): VOLUNTARY ANNOUNCEMENT-TRANSCENTA PRESENTS NEW DATA FOR ITS NOVEL LIV1-TARGETING ADC TST013 DEMONSTRATING POTENT ANTI-TUMOR ACTIVITY ... | - | HKEx | ||
| 08.04. | TRANSCENTA-B (06628): (1) CHANGE OF STOCK SHORT NAME; AND (2) CHANGE OF COMPANY LOGO | 1 | HKEx | ||
| 31.03. | TRANSCENTA-B (06628): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | 1 | HKEx | ||
| 30.03. | Transcenta Therapeutics Appoints Dr. Christopher Hwang as Head of Global Partnerships for HiCB Platform | 2 | GlobeNewswire (USA) | ||
| 18.03. | TRANSCENTA-B (06628): DATE OF BOARD MEETING | 1 | HKEx | ||
| 24.02. | TRANSCENTA-B (06628): VOLUNTARY ANNOUNCEMENT-TRANSCENTA TO PRESENT AT THE 36TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE | 2 | HKEx |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TANGO THERAPEUTICS | 30,940 | +0,03 % | Tango Therapeutics stock soars on promising pancreatic cancer data | ||
| NURIX THERAPEUTICS | 15,640 | 0,00 % | Roche geht 2,3-Milliarden-Dollar-Deal mit Nurix für Blutkrebsmittel ein | DJ Roche geht 2,3-Milliarden-Dollar-Deal mit Nurix für Blutkrebsmittel ein
Von Nina Kienle
DOW JONES--Roche hat mit dem US-Biotechunternehmen Nurix Therapeutics eine exklusive Lizenz- und Kooperationsvereinbarung... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,110 | 0,00 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| COGENT BIOSCIENCES | 31,160 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 82,94 | -0,08 % | RBC Capital raises Apogee Therapeutics stock price target to $97 | ||
| PRAXIS PRECISION MEDICINES | 253,12 | -0,05 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ERASCA | 12,870 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,780 | 0,00 % | Beam Therapeutics Inc. - 8-K, Current Report | ||
| AMYLYX PHARMACEUTICALS | 13,010 | 0,00 % | H.C. Wainwright reiterates Amylyx stock rating on PBH trial insights | ||
| KINIKSA PHARMACEUTICALS | 49,040 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 22,500 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 17,000 | 0,00 % | Pictet closes $1.53bn Monte Rosa Co-Investments VI fund, exceeding target | ||
| DYNE THERAPEUTICS | 16,820 | +0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1) | - Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage... ► Artikel lesen | |
| CG ONCOLOGY | 54,36 | -0,07 % | CG Oncology, Inc. - 8-K, Current Report | ||
| RELAY THERAPEUTICS | 13,660 | 0,00 % | Relay Therapeutics Shares Jump 18% |
Das Unternehmen TRANSCENTA HOLDING LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCENTA HOLDING LTD finden Sie auf Wallstreet Online.